United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer CEO Albert Bourla said he's confident the full results from the clinical trials will show that the oral antiviral pill, Paxlovid, reduces Covid hospitalization and death by 89%.

Pfizer will submit full data on Covid treatment pill to the FDA in a few days, CEO says

It has been a volatile couple of weeks for Covid-19 vaccine makers, as investors battle to assess the impact of the Omicron variant while waiting for answers to crucial questions.

Pfizer Says 3 Doses of Its Vaccine Are Effective Against Omicron

The vaccine has “significantly reduced” protection against omicron after only two shots, early data suggests.

Pfizer Covid-19 Booster ‘Neutralizes' Omicron Variant, Company Says

The companies did not release the full preliminary data that led to their findings, opting instead to only issue a press release.

Pfizer says booster dose of COVID vaccine neutralizes Omicron variant.

BioNTech SE

Yields for U.S. government debt on Wednesday were trading mixed as investors digested news suggesting the omicron variant of coronavirus that causes COVID-19 may not impact the economy as much as feared.

Bond Report: U.S. Treasury yields steady after Pfizer/BioNTech omicron report

A small study in South Africa shows that the omicron variant can partially evade protection from two doses of Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine. But the study did show that blood from people who had received two doses of the vaccine and had a prior infection were primarily able to neutralize the variant, thus suggesting booster doses of the vaccine could help to fend off the infection.

Pfizer/BioNTech COVID-19 Shot Provides Partial Protection Against Omicron, Study Shows

Pfizer and BioNTech say three doses of their Covid-19 vaccine neutralize the Omicron variant, according to results of an initial laboratory study.

Pfizer Says Three Doses of Its Covid Vaccine Neutralizes Omicron Variant

Pfizer and BioNTech said lab tests showed that two doses appeared less effective against Omicron, though it still protects against severe disase.

Pfizer says 3 of its shots work against Omicron, but that 2 are significantly less effective

Three shots of the Pfizer/BioNTech COVID-19 vaccine has been shown to generate a neutralising effect against the new Omicron variant in a laboratory test.

Three doses of Pfizer jab can 'neutralise' Omicron variant, lab test shows

A booster shot of the vaccine increases antibody protection 25-fold compared with the initial two-dose series, according to a preliminary lab study.

Pfizer-BioNTech say booster dose provides high level of protection against omicron variant

Pfizer Inc. PFE, +0.47% and BioNTech SE BNTX, +8.17% said results from an "initial laboratory study" showed that their COVID-19 vaccine neutralized the omicron variant of the coronavirus after three doses, or the full two-dose regimen plus a booster shot. The drug makers said those who received just two does of the vaccine showed, on average, a more than 25-fold reduction in neutralization against the omicron variant.

Pfizer, BioNTech say initial lab study showed 3 doses of COVID-19 vaccine neutralized omicron variant

NEW YORK and MAINZ, Germany, December 8, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an initial laboratory study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to those observed for the wild-type SARS-CoV-2 spike protein after two doses.

Pfizer and BioNTech Provide Update on Omicron Variant

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an initial laboratory study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to those obse

Pfizer and BioNTech Provide Update on Omicron Variant.

Prof. Alex Sigal with the Africa Health Research Institute and a team of scientists tested blood samples of 12 people who'd previously been vaccinated with the Pfizer/BioNTech vaccine.

Omicron significantly reduces Covid antibody protection in small study of Pfizer vaccine recipients

AstraZeneca

Moderna

A British study evaluating mixing COVID-19 vaccines showed a better immune response in people after the first dose of AstraZeneca Plc (NASDAQ: AZN) or Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) shots followed by Moderna Inc's (NASDAQ: MRNA) nine weeks later. AstraZeneca-Oxford vaccine followed by a Moderna or Novavax Inc (NASDAQ: NVAX) shot showed higher antibodies and T-cell responses versus two doses of AstraZeneca-Oxford.

Mix & Match Pfizer, AstraZeneca COVID-19 Vaccine With Moderna Shows Improved Immune Response

Merck

In a race with Merck & Co Inc (NYSE: MRK) to get antivirals to market, Pfizer Inc (NYSE: PFE) CEO Albert Bourla told the Wall Street Journal's CEO Council that he expects its antiviral pill will hit the U.S. market before the end of this month. Data from Pfizer's pill, Paxlovid, showed an 89% reduction in COVID- 19 related hospitalization or deaths in an interim analysis compared to placebo in patients treated within three days of symptom onset.

Pfizer, Merck COVID-19 Pills US Launch In This Month; Other Countries Will Have to Wait: WSJ

The European Commission recently approved Pfizer's Xeljanz to treat patients with ankylosing spondylitis.

What This Label Expansion Means for Pfizer

“I don't think it's good news to have something that spreads fast,” Pfizer CEO Albert Bourla told The Wall Street Journal.

Pfizer CEO says omicron appears milder but spreads faster and could lead to more Covid mutations

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to access a live webcast of a presentation and conference call with investment analysts at 8:30 a.m. EST on Friday, December 17, 2021. Pfizer Vaccines and Hospital leadership will discuss the Pfizer-BioNTech COVID-19 vaccine and Pfizer's novel COVID-19 oral antiviral treatment candidate. To access the webcast and presentation slides, visit our web site at www.pfizer.com/investors. Information on accessin

Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate

Novavax

Stocks of Moderna (MRNA), BioNTech (BNTX), Novavax (NVAX) and Pfizer (PFE) decline as data suggests that Omicron variant may cause less severe cases of COVID-19.

Vaccine Stocks Down as Omicron May Not Be Too Severe

The stock price of Pfizer Inc. (NYSE: PFE) fell by 5.14% today. This is why it happened.

Pfizer Stock (PFE): Why The Price Dropped Today

Dr. Fauci has implied that the omicron variant may not be as severe as feared. Vaccine stocks have taken a hit as a result.

Vaccine Stocks: Why MRNA, BNTX, NVAX, PFE Stocks Are Stumbling Today

Johnson & Johnson

Big declines show the uncertainty investors have about the future of fighting COVID-19.

Vaccine Stocks: The Beginning of the End?

From the Cleveland Clinic, one of the teams reports it has found a potential Alzheimer's treatment in one of the world's most famous drugs - Pfizer Inc's (NYSE: PFE) erectile dysfunction treatment Viagra (sildenafil). The Cleveland Clinic researchers screened a database of 7 million patients and found that Viagra is associated with a 69% lower incidence of Alzheimer's disease.

Can Pfizer's Viagra Help In Alzheimer's? Cleveland Clinic Study Shows Potential

Ocugen, Inc.

Vaxart

The initial data on omicron suggests that the pandemic has entered a new, less deadly phase.

News for Pfizer Stock (PFE)